FBRX Share Price | Forte Biosciences, Inc. Stock Analysis & Recommendation

Q: What does Forte Biosciences, Inc. do?

Overview: Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a live biotherapeutic for the treatment of inflammatory skin diseases, particularly for pediatric atopic dermatitis patients, and operates within the Pharmaceuticals & Biotechnology industry in the micro-cap market.Financial Snapshot: Most recent Net Profit: -16 Million (Quarterly Results - Mar 2025) Market cap: USD 81.50 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.19 Return on Equity: -113.76% Price to Book: 2.12Contact Details: Address: 1124 W Carson Street, Mrl Building 3-320, TORRANCE CA: 90502 Tel: ['1 310 6186994', '1 415 5159763'] Fax: 1 302 6555049 Website: https://tocagen.com

Q: Is Forte Biosciences, Inc. overvalued or undervalued?

As of 12 November 2019, the valuation grade for Forte Biosciences, Inc. moved from risky to does not qualify, indicating a significant downgrade in its financial standing. The company is currently considered overvalued based on its financial ratios and peer comparisons. Key ratios include a Price to Book Value of 1.94, a negative ROE of -113.76%, and an EV to EBITDA ratio of -0.64, which reflects a lack of profitability.In comparison to its peers, Forte Biosciences shows a stark contrast; for instance, Pieris Pharmaceuticals, Inc. has a P/E ratio of -13.97 and an EV to EBITDA of -9.60, while OncoCyte Corp. is rated risky with an EV to EBITDA of -2.86. The company's recent performance has also been poor, with a year-to-date return of -43.81%, significantly underperforming the S&P 500, which has returned 2.44% in the same period. Overall, the combination of negative financial metrics and poor peer performance suggests that Forte Biosciences is currently overvalued.

Q: Is Forte Biosciences, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Forte Biosciences, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly KST and OBV are also mildly bearish. Although the MACD is bullish on a weekly basis and mildly bullish on a monthly basis, the overall sentiment is tempered by the bearish indicators. The stock has shown strong short-term performance with a 26.29% return over the past week, significantly outperforming the S&P 500's 1.05%, but it remains down 41.83% year-to-date compared to the S&P's 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

60.62 k

Shareholding (Sep 2025)

FII

11.49%

Held by 16 FIIs

DII

48.39%

Held by 32 DIIs

Promoter

9.63%

How big is Forte Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Forte Biosciences, Inc. has a market capitalization of 81.50 million and reported net sales of 0.00 million with a net profit of -43.72 million over the last four quarters. The balance sheet shows shareholder's funds of 52.48 million and total assets of 61.56 million.

View full answer

What does Forte Biosciences, Inc. do?

22-Jun-2025

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company developing live biotherapeutics for inflammatory skin diseases, particularly pediatric atopic dermatitis. It operates in the micro-cap market with a market cap of $81.50 million and reported a net profit loss of $16 million as of March 2025.

View full answer

Who are in the management team of Forte Biosciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Forte Biosciences, Inc. is led by Dr. Paul Wagner as Chairman, President, and CEO, with the board of directors including Mr. Thomas Darcy, Dr. Lawrence Eichenfield, Mr. Steven Kornfeld, Dr. Patricia Walker, and Mr. Donald Williams.

View full answer

Is Forte Biosciences, Inc. overvalued or undervalued?

25-Jun-2025

Forte Biosciences, Inc. is currently considered overvalued due to negative financial metrics, including a Price to Book Value of 1.94 and a negative ROE of -113.76%, alongside poor performance compared to peers and a year-to-date return of -43.81%.

View full answer

Is Forte Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Forte Biosciences, Inc. is in a mildly bearish trend despite a strong short-term performance of 26.29%, with bearish indicators outweighing a bullish MACD.

View full answer

Compare Forte Biosciences, Inc. with Similar Stocks

Pluri, Inc.Rain Oncology, Inc.Seelos Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 344 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.11

Return on Equity

-61.53%

Price to Book

4.09

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-18 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-18.23%

6 Months

77.9%

1 Year

327.27%

2 Years

46.14%

3 Years

2250.0%

4 Years

-36.49%

5 Years

-96.43%

Forte Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-0.20%

EBIT Growth (5y)

-51.07%

EBIT to Interest (avg)

-26.83

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.19

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

86.89%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.09

EV to EBIT

-4.69

EV to EBITDA

-4.69

EV to Capital Employed

-26.89

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-61.53%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 7 Schemes (30.49%)

Foreign Institutions

Held by 16 Foreign Institutions (11.49%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -110.71% vs 16.00% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.40",
          "val2": "-8.60",
          "chgp": "-113.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.70",
          "val2": "-8.40",
          "chgp": "-110.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -12.70% vs -126.62% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-36.60",
          "val2": "-32.50",
          "chgp": "-12.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-35.50",
          "val2": "-31.50",
          "chgp": "-12.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-18.40

-8.60

-113.95%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-17.70

-8.40

-110.71%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is -110.71% vs 16.00% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-36.60

-32.50

-12.62%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-35.50

-31.50

-12.70%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -12.70% vs -126.62% in Dec 2023

All Annual Results

Company CV

About Forte Biosciences, Inc.

Forte Biosciences, Inc.

Pharmaceuticals & Biotechnology

Forte Biosciences, Inc., formerly Tocagen Inc., is a clinical-stage biopharmaceutical company. The Company is focused on clinical program and developing a live biotherapeutic for the treatment of inflammatory skin diseases, particularly for pediatric atopic dermatitis patients. It provides FB-401, which is a live biotherapeutic for the treatment of inflammatory skin diseases. FB-401 has completed Phase I/II a testing in adult and pediatric patients with atopic dermatitis.

Company Coordinates

Company Details

1124 W Carson Street, Mrl Building 3-320 , TORRANCE CA : 90502

Tel: 1 310 61869941 415 5159763

https://tocagen.com

Registrar Details